Coalition Forms To Influence Scheduling Review Process -
As the Biden administration actively reviews the classification of cannabis under the Controlled Substances Act (CSA), a diverse group of cannabis companies and...more
Cannabis: In Focus -
- DEA Classifies Two Lab-Derived Cannabinoids as Schedule I
- Washington Federal Judge Dismisses Suit Challenging Residency Requirements...more
3/7/2023
/ Appeals ,
Cannabidiol (CBD) oil ,
Cannabis Products ,
Commercial Litigation ,
DEA ,
Dismissals ,
Food and Drug Administration (FDA) ,
Investors ,
Licenses ,
Marijuana ,
Non-Residents ,
Schedule I Drugs ,
THC ,
Washington
Seattle Federal Court Dismisses Dormant Commerce Clause Challenge -
A Seattle-based federal court dismissed a challenge to a state residency requirement to hold equity in Washington state cannabis businesses. The...more
Cannabis: In Focus -
Cannabis Banking Reform Possible During Lame-Duck Session -
Nevada Court Removes Cannabis from State’s Controlled Substances List...more
Cannabis as Schedule I Substance Violates State’s Constitution -
On September 14, 2022, Clark County District Judge Joe Hardy Jr. ruled that the Nevada Board of Pharmacy’s classification of cannabis as a Schedule I...more
Second Circuit Rules That Cannabis As a Schedule I Under CSA Is Constitutional -
This August, the U.S. Court of Appeals for the Second Circuit affirmed a lower court’s ruling that the government’s classification of...more
9/8/2022
/ Appeals ,
Appellate Courts ,
Cannabis Products ,
Controlled Substances Act ,
Fifth Amendment ,
Legislative Agendas ,
Medical Marijuana ,
Preliminary Injunctions ,
Reversal ,
Schedule I Drugs ,
State and Local Government ,
Vacated